Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PharmaMar, Jazz get FDA priority review for lurbinectedin in relapsed SCLC
As per the new drug application (NDA) for lurbinectedin, which has been accepted for filing by the regulator, the two companies are seeking accelerated approval for its use
As per the new drug application (NDA) for lurbinectedin, which has been accepted for filing by the regulator, the two companies are seeking accelerated approval for its use
With the FDA’s approval, Voltaren Arthritis Pain becomes the first and only prescription strength, nonsteroidal anti-inflammatory (NSAID) topical gel for arthritis pain available OTC in the United States.
The company said that 26% of patients with previously treated advanced or metastatic renal cell carcinoma are alive at five years of treatment with Opdivo. According to Bristol-Myers
Results presented at The European Crohn’s and Colitis Organisation (ECCO) 2020 annual congress in Vienna, Austria demonstrated that the SC formulation of CT-P13 was comparable to the IV
This NDA requests FDA approval of tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients
Vivo Capital was the lead investor with other new investors including funds managed by Logos Capital, Janus Henderson, Foresite Capital, Cormorant Asset Management, BVF Partners, and investor HBM
As per the new drug application (NDA) that has been accepted by the FDA, Novartis is seeking approval for the use of capmatinib as a treatment for first-line
The business comprises of a portfolio of 62 brands in multiple therapy areas such as Respiratory, Neurology, VMS, Dermatology, Gastroenterology, Pain and Vaccines, which would transfer to Dr.
Based on the result of the primary endpoint, Lilly has dropped its plan to pursue regulatory submission for solanezumab in people having dominantly inherited Alzheimer’s disease (DIAD) or
The Company also announced three new vaccine development candidates, which support the Company’s strategy, announced January 12, to accelerate new development candidates in its core modalities, prophylactic vaccines